Citations (139)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Lin Fan, Yiwen You, Yao Fan, Chong Shen & Yong Xue. (2021) Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 1289-1297.
Read now
Read now
Raul Escamilla, Beatriz Camarena, Ricardo Saracco-Alvarez, Ana Fresán, Sandra Hernández & Alejandro Aguilar-García. (2018) Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatric Disease and Treatment 14, pages 2981-2987.
Read now
Read now
John Lally, Fiona Gaughran, Philip Timms & Sarah R Curran. (2016) Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmacogenomics and Personalized Medicine 9, pages 117-129.
Read now
Read now
Seenae Eum, Adam M. Lee & Jeffrey R. Bishop. (2016) Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues in Clinical Neuroscience 18:3, pages 323-337.
Read now
Read now
Jennie G. Pouget, Tahireh A. Shams, Arun K. Tiwari & Daniel J. Müller. (2014) Pharmacogenetics and outcome with antipsychotic drugs. Dialogues in Clinical Neuroscience 16:4, pages 555-566.
Read now
Read now
C. Anthony Altar, John Hornberger, Ashwini Shewade, Victor Cruz, Jill Garrison & David Mrazek. (2013) Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. International Review of Psychiatry 25:5, pages 509-533.
Read now
Read now
Jian-Ping Zhang & Anil K Malhotra. (2013) Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opinion on Drug Metabolism & Toxicology 9:2, pages 183-191.
Read now
Read now
Jay Lombard & P Murali Doraiswamy. (2013) What is the role of pharmacogenetics in clinical psychiatry?. Expert Opinion on Drug Metabolism & Toxicology 9:1, pages 1-4.
Read now
Read now
Articles from other publishers (131)
Amrit K. Sandhu, Elnaz Naderi, Morenika J. Wijninga, Edith J. Liemburg, Danielle Cath, Richard Bruggeman & Behrooz Z. Alizadeh. (2023) Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19. Journal of Personalized Medicine 13:9, pages 1354.
Crossref
Crossref
Eden B. Maness, Sarah A. Blumenthal & Joshua A. Burk. (2023) Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia. Behavioural Brain Research 450, pages 114497.
Crossref
Crossref
Rachel L. Moster. (2023) Ethnic Differences in Antipsychotic Response: What Genetic Variation Does and Does Not Tell Us. Current Behavioral Neuroscience Reports.
Crossref
Crossref
E. E. Vaiman & L. P. Linova. (2023) Antipsychotic-Induced Parkinsonism and Dyskinesia in a 43- years Old Male with Schizophrenia: Clinical Case. Personalized Psychiatry and Neurology 3:1, pages 48-52.
Crossref
Crossref
Jonathan Tamaiev, Zachary Bergson, Xiaowei Sun, Dipta Roy, Gunjan Desai, Todd Lencz, Anil Malhotra & Jian-Ping Zhang. (2023) Patient Attitudes Toward Pharmacogenetic Testing in Psychiatric Treatment. Current Behavioral Neuroscience Reports 10:2, pages 30-40.
Crossref
Crossref
Adrianna Szczakowska, Agata Gabryelska, Oliwia Gawlik-Kotelnicka & Dominik Strzelecki. (2023) Deep Brain Stimulation in the Treatment of Tardive Dyskinesia. Journal of Clinical Medicine 12:5, pages 1868.
Crossref
Crossref
Adriana Stelmach, Katarzyna Guzek, Alicja Rożnowska, Irena Najbar & Anna Sadakierska-Chudy. (2022) Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacological Reports 75:1, pages 19-31.
Crossref
Crossref
Pratyusha Attaluri, Ayeshah G. Mohiuddin, Kowsar Teymouri & James L. Kennedy. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
17
.
Abdul Kadir, Jasdeep Singh, Vikrant Rahi & Puneet Kumar. (2022) Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats. Neurochemical Research 47:11, pages 3285-3297.
Crossref
Crossref
Alejandra Zazueta, Tito Castillo, Álvaro Cavieres, René González, Maximiliano Abarca, Rodrigo R Nieto, Javier Deneken, Cristian Araneda, Pablo R Moya & M Leonor Bustamante. (2022) Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness. International Journal of Neuropsychopharmacology 25:9, pages 701-708.
Crossref
Crossref
Wielandt N. Ana María, Moreno C. Mauricio & Ortiz L. Lina. (2022) Uso de la farmacogenética como herramienta de precisión en psiquiatría: hacia una medicina personalizada. Revista Médica Clínica Las Condes 33:2, pages 163-173.
Crossref
Crossref
Pan Yan, Bing Gao, Shuqi Wang, Shengdong Wang, Jing Li & Mingfen Song. (2022) Association of 5-HTR2A T102C and A-1438G polymorphisms with clinical response to atypical antipsychotic treatment in schizophrenia: A meta-analysis. Neuroscience Letters 770, pages 136395.
Crossref
Crossref
Niamh M. Ryan, Cathal Ormond, Philip Brady, Elizabeth A. Heron & Aiden Corvin. 2022. Psychiatric Genomics. Psychiatric Genomics
17
41
.
Samar S. M. Elsheikh, Daniel J. Müller & Jennie G. Pouget. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
389
425
.
Alberto Ortega‐Vázquez, Yerye G. Mayen‐Lobo, David J. Dávila‐Ortiz de Montellano, Luis Tristán‐López, Carlos L. Aviña‐Cervantes, Camilo Ríos, Marisol López‐López & Nancy Monroy‐Jaramillo. (2020)
Alcohol intake potentiates clozapine adverse effects associated to
CYP1A2
*
1C
in patients with refractory psychosis
. Drug Development Research 82:5, pages 685-694.
Crossref
Crossref
Rizaldy C. Zapata, Besma S. Chaudry, Mariela Lopez Valencia, Dinghong Zhang, Scott A. Ochsner, Neil J. McKenna & Olivia Osborn. (2021) Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain. Translational Psychiatry 11:1.
Crossref
Crossref
Saki Hattori, Akira Suda, Masatoshi Miyauchi, Yohko Shiraishi, Takashi Saeki, Tadashi Fukushima, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Tosiho Moritani, Yusuke Saigusa & Ikuko Kishida. (2020) The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. BMC Psychiatry 20:1.
Crossref
Crossref
Pan Yan, Mingfen Song, Bing Gao, Shuqi Wang, Shengdong Wang, Jing Li, Haihong Fang, Chengpeng Wang & Jianfei Shi. (2020) Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients. Psychiatry Research 293, pages 113470.
Crossref
Crossref
Nadine C. van der Burg, Asmar F. Y. Al Hadithy, Peter N. van Harten, Jim van Os & P. Roberto Bakker. (2020) The genetics of drug-related movement disorders, an umbrella review of meta-analyses. Molecular Psychiatry 25:10, pages 2237-2250.
Crossref
Crossref
Xu You, Yunqiao Zhang, Qing Long, Zijun Liu, Xiao Ma, Zixiang Lu, Wei� Yang, Ziqiao Feng, Wengyu Zhang, Zhaowei Teng & Yong Zeng. (2020) Investigating aberrantly expressed microRNAs in peripheral blood mononuclear cells from patients with treatment‑resistant schizophrenia using miRNA sequencing and integrated bioinformatics. Molecular Medicine Reports.
Crossref
Crossref
Paola Giusti-Rodríguez, James G Xenakis, James J Crowley, Randal J Nonneman, Daniela M DeCristo, Allison Ryan, Corey R Quackenbush, Darla R Miller, Ginger D Shaw, Vasyl Zhabotynsky, Patrick F Sullivan, Fernando Pardo Manuel de Villena & Fei Zou. (2020) Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX). G3 Genes|Genomes|Genetics 10:9, pages 3165-3177.
Crossref
Crossref
Elisabetta Maffioletti, Paolo Valsecchi, Alessandra Minelli, Chiara Magri, Cristian Bonvicini, Stefano Barlati, Emilio Sacchetti, Antonio Vita & Massimo Gennarelli. (2020)
Association study between
HTR2A
rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients
. Drug Development Research 81:6, pages 754-761.
Crossref
Crossref
M. N. Grunina, A. M. Zabotina, A. S. Zhuravlev, M. M. Pchelina, E. V. Volkova, R. F. Nasyrova, A. E. Taraskina & E. M. Krupitsky. (2020) DOPAMINE RECEPTOR D2 (DRD2) IN PERIPHERAL BLOOD LYMPHOCYTES AS BIOMARKER OF RESPONSE TO ANTIPSYCHOTIC MEDICATION. The Scientific Notes of the Pavlov University 27:1, pages 45-56.
Crossref
Crossref
Mei Han & Chao Deng. (2020) BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neuroscience Letters 726, pages 133870.
Crossref
Crossref
Mirko Grubor, Maja Zivkovic, Marina Sagud, Matea Nikolac Perkovic, Alma Mihaljevic-Peles, Nela Pivac, Dorotea Muck-Seler & Dubravka Svob Strac. (2020) HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia. International Journal of Molecular Sciences 21:7, pages 2345.
Crossref
Crossref
Roksana Zakharyan, Hovsep Ghazaryan, Lenka Kocourkova, Andranik Chavushyan, Artur Mkrtchyan, Veronika Zizkova, Arsen Arakelyan & Martin Petrek. (2020) Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia. Archives of Medical Research 51:1, pages 13-20.
Crossref
Crossref
Sophie E. Legge, Antonio F. Pardiñas & James T.R. Walters. 2020. Personalized Psychiatry. Personalized Psychiatry
413
422
.
A. Corvin, C. Ormond & A.M. Cole. 2020. Personalized Psychiatry. Personalized Psychiatry
173
186
.
Yanmiao CAO & Wenxin ZHANG. (2022) The influence of dopaminergic genetic variants and maternal parenting on adolescent depressive symptoms: A multilocus genetic study. Acta Psychologica Sinica 51:10, pages 1102-1115.
Crossref
Crossref
Xueping Wang, Yi Su, Hao Yan, Zhuo Huang, Yu Huang & Weihua Yue. (2019) Association Study of KCNH7 Polymorphisms and Individual Responses to Risperidone Treatment in Schizophrenia. Frontiers in Psychiatry 10.
Crossref
Crossref
Nicolas Tournier, Martin Bauer, Verena Pichler, Lukas Nics, Eva-Maria Klebermass, Karsten Bamminger, Peter Matzneller, Maria Weber, Rudolf Karch, Fabien Caillé, Sylvain Auvity, Solène Marie, Walter Jäger, Wolfgang Wadsak, Marcus Hacker, Markus Zeitlinger & Oliver Langer. (2019)
Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate
11
C-Metoclopramide Assessed with PET Imaging in Humans
. Journal of Nuclear Medicine 60:7, pages 985-991.
Crossref
Crossref
Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan, Cynthia Marie‐Claire, Frank Bellivier & Deepak Gopal Shewade. (2018)
Dopamine (
DRD
2
) and Serotonin (
HTR
2A, 2C)
Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia
. Fundamental & Clinical Pharmacology 33:3, pages 355-364.
Crossref
Crossref
Wei Zhou, Yong Xu, Qinyu Lv, Yong-hui Sheng, Luan Chen, Mo Li, Lu Shen, Cong Huai, Zhenghui Yi, Donghong Cui & Shengying Qin. (2019) Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients. Frontiers in Pharmacology 10.
Crossref
Crossref
Antonio Rampino, Aleksandra Marakhovskaia, Tiago Soares-Silva, Silvia Torretta, Federica Veneziani & Jean Martin Beaulieu. (2019) Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects. Frontiers in Psychiatry 9.
Crossref
Crossref
Lingyue Ma, Xiaodan Zhang, Qian Xiang, Shuang Zhou, Nan Zhao, Qiufen Xie, Xia Zhao, Ying Zhou & Yimin Cui. (2018) Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta‐analysis. Basic & Clinical Pharmacology & Toxicology 124:1, pages 94-104.
Crossref
Crossref
M. Na Takuathung, N. Hanprasertpong, S. Teekachunhatean & N. Koonrungsesomboon. (2018)
Impact of
CYP1A2
genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta‐analysis
. Acta Psychiatrica Scandinavica 139:1, pages 15-25.
Crossref
Crossref
Yun-Ai Su, Chad Bousman, Qian Li, Ji-Tao Li, Jing-Yu Lin & Tian-Mei Si. (2018) Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia. Journal of Neural Transmission 126:1, pages 19-25.
Crossref
Crossref
Anabel Perez-Gomez, Maria Carretero, Natalie Weber, Veronika Peterka, Alan To, Viktoriya Titova, Gregory Solis, Olivia Osborn & Michael Petrascheck. (2018) A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia. Nature Communications 9:1.
Crossref
Crossref
Osmar Henrique Della Torre, Lúcia Arisaka Paes, Taciane Barbosa Henriques, Maricilda Palandi de Mello, Eloisa Helena Rubello Valler Celeri, Paulo Dalgalarrondo, Gil Guerra-Júnior & Amilton dos Santos-Júnior. (2018) Dopamine D2 receptor gene polymorphisms and externalizing behaviors in children and adolescents. BMC Medical Genetics 19:1.
Crossref
Crossref
Tonya Gross & Jeremy Daniel. (2018) Overview of pharmacogenomic testing in clinical practice. Mental Health Clinician 8:5, pages 235-241.
Crossref
Crossref
Wei Zhou, Wushao Chang, Yucai Yan, Lu Shen, Wenqiang Li, Zhenghui Yi & Shengying Qin. (2018) Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients. Neuroscience Letters 683, pages 202-206.
Crossref
Crossref
Manuel A. Franco-Martin, Francisco Sans, Belen García-Berrocal, Cristina Blanco, Carlos Llanes-Alvarez & María Isidoro-García. (2018) Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report. Clinical Psychopharmacology and Neuroscience 16:3, pages 349-357.
Crossref
Crossref
Peggy Bosch, Sabina Lim, Heike Staudte, Sujung Yeo, Sook-Hyun Lee, Pia Barisch, Benoît Perriard & Maurits Van den Noort. (2018) Pharmacological Treatment for Long-Term Patients with Schizophrenia and Its Effects on Sleep in Daily Clinical Practice: A Pilot Study. Medicines 5:2, pages 44.
Crossref
Crossref
Hao Yu, Hao Yan, Lifang Wang, Jun Li, Liwen Tan, Wei Deng, Qi Chen, Guigang Yang, Fuquan Zhang, Tianlan Lu, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xiao Xiao, Ming Li, Xin Ma, Fude Yang, Lingjiang Li, Chuanyue Wang, Tao Li, Dai Zhang & Weihua Yue. (2018) Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. The Lancet Psychiatry 5:4, pages 327-338.
Crossref
Crossref
Jian-Ping Zhang & Anil K. Malhotra. (2018) Recent Progress in Pharmacogenomics of Antipsychotic Drug Response. Current Psychiatry Reports 20:4.
Crossref
Crossref
Maurits van den Noort, Sujung Yeo, Sabina Lim, Sook-Hyun Lee, Heike Staudte & Peggy Bosch. (2018) Acupuncture as Add-On Treatment of the Positive, Negative, and Cognitive Symptoms of Patients with Schizophrenia: A Systematic Review. Medicines 5:2, pages 29.
Crossref
Crossref
Jesus Sainz, Carlos Prieto, Fulgencio Ruso-Julve & Benedicto Crespo-Facorro. (2018) Blood Gene Expression Profile Predicts Response to Antipsychotics. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
Beom S. Lee, Roger S. McIntyre, James E. Gentle, Nan Sook Park, David A. Chiriboga, Yena Lee, Sabrina Singh & Marie A. McPherson. (2018) A computational algorithm for personalized medicine in schizophrenia. Schizophrenia Research 192, pages 131-136.
Crossref
Crossref
Jeffrey R. Bishop. 2018. Neurogenetics, Part I. Neurogenetics, Part I
59
73
.
Seung-Gul Kang, Ik-Seung Chee, Hun Soo Chang, Kyoung-Sae Na, Kwanghun Lee & Jonghun Lee. (2017) Polymorphism of the SNAP25 gene is associated with symptom improvement in schizophrenic patients treated with amisulpride. Neuroscience Letters 661, pages 46-50.
Crossref
Crossref
Claire Foley, Aiden Corvin & Shigeki Nakagome. (2017) Genetics of Schizophrenia: Ready to Translate?. Current Psychiatry Reports 19:9.
Crossref
Crossref
Austen B. Casey & Clinton E. Canal. (2017) Classics in Chemical Neuroscience: Aripiprazole. ACS Chemical Neuroscience 8:6, pages 1135-1146.
Crossref
Crossref
Jian-Ping Zhang & Anil K. Malhotra. (2017) Pharmacogenomics of Antipsychotic Drugs. Current Treatment Options in Psychiatry 4:2, pages 127-138.
Crossref
Crossref
Matea Perkovic, Gordana Erjavec, Dubravka Strac, Suzana Uzun, Oliver Kozumplik & Nela Pivac. (2017) Theranostic Biomarkers for Schizophrenia. International Journal of Molecular Sciences 18:4, pages 733.
Crossref
Crossref
E Sacchetti, C Magri, A Minelli, P Valsecchi, M Traversa, S Calza, A Vita & M Gennarelli. (2016) The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. The Pharmacogenomics Journal 17:2, pages 146-154.
Crossref
Crossref
Seung-Gul Kang, Ik-Seung Chee, Kwanghun Lee & Jonghun Lee. (2017)
rs
7968606 polymorphism of
ANKS1B
is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride
. Human Psychopharmacology: Clinical and Experimental 32:2, pages e2562.
Crossref
Crossref
Johann Steiner, Paul C. Guest & Daniel Martins-de-Souza. 2017. Proteomic Methods in Neuropsychiatric Research. Proteomic Methods in Neuropsychiatric Research
3
19
.
Johann Steiner, Paul C. Guest, Hassan Rahmoune & Daniel Martins-de-Souza. 2017. Multiplex Biomarker Techniques. Multiplex Biomarker Techniques
19
35
.
Jian-Ping Zhang, Todd Lencz, Ryan X. Zhang, Masahiro Nitta, Lawrence Maayan, Majnu John, Delbert G. Robinson, W. Wolfgang Fleischhacker, Rene S. Kahn, Roel A. Ophoff, John M. Kane, Anil K. Malhotra & Christoph U. Correll. (2016) Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophrenia Bulletin 42:6, pages 1418-1437.
Crossref
Crossref
Jiamei Lian, Bo Pan & Chao Deng. (2016) Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacological Reports 68:5, pages 1028-1035.
Crossref
Crossref
Q Xu, X Wu, M Li, H Huang, C Minica, Z Yi, G Wang, L Shen, Q Xing, Y Shi, L He & S Qin. (2015) Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. The Pharmacogenomics Journal 16:4, pages 357-365.
Crossref
Crossref
C. Adithan. (2019) Bringing pharmacogenomics and personalized medicine into clinical practice. Annals of SBV 5:1, pages 9-13.
Crossref
Crossref
G B Rogers, D J Keating, R L Young, M-L Wong, J Licinio & S Wesselingh. (2016) From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Molecular Psychiatry 21:6, pages 738-748.
Crossref
Crossref
Donald C. Goff, Klaus Romero, Jeffrey Paul, M. Mercedes Perez-Rodriguez, David Crandall & Steven G. Potkin. (2016) Biomarkers for drug development in early psychosis: Current issues and promising directions. European Neuropsychopharmacology 26:6, pages 923-937.
Crossref
Crossref
Michael Camilleri, Lionel Buéno, Viola Andresen, Fabrizio De Ponti, Myung-Gyu Choi & Anthony Lembo. (2016) Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology 150:6, pages 1319-1331.e20.
Crossref
Crossref
Jiamei Lian, Xu-Feng Huang, Nagesh Pai & Chao Deng. (2016) Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications. Pharmacological Research 106, pages 51-63.
Crossref
Crossref
Douglas M Ruderfer, Alexander W Charney, Ben Readhead, Brian A Kidd, Anna K Kähler, Paul J Kenny, Michael J Keiser, Jennifer L Moran, Christina M Hultman, Stuart A Scott, Patrick F Sullivan, Shaun M Purcell, Joel T Dudley & Pamela Sklar. (2016) Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. The Lancet Psychiatry 3:4, pages 350-357.
Crossref
Crossref
John Lally & James H. MacCabe. (2018) Personalised approaches to pharmacotherapy for schizophrenia. BJPsych Advances 22:2, pages 78-86.
Crossref
Crossref
A. K. Martin & B. Mowry. (2015) Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. Psychological Medicine 46:3, pages 469-476.
Crossref
Crossref
Florence Gressier, Stefano Porcelli, Raffaella Calati & Alessandro Serretti. (2016) Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. European Neuropsychopharmacology 26:2, pages 163-185.
Crossref
Crossref
Amilton Dos Santos-Júnior, Taciane Barbosa Henriques, Maricilda Palandi de Mello, Osmar Henrique Della Torre, Lúcia Arisaka Paes, Adriana Perez Ferreira-Neto, Letícia Esposito Sewaybricker, Thiago Salum Fontana, Eloisa Helena Rubello Valler Celeri, Gil Guerra-Júnior & Paulo Dalgalarrondo. (2016) Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents. International Journal of Endocrinology 2016, pages 1-10.
Crossref
Crossref
Roy H. Perlis. 2016. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry
727
747
.
Amilton dos Santos JúniorTaciane Barbosa HenriquesMaricilda Palandi de MelloAdriana Perez Ferreira NetoLúcia Arisaka PaesOsmar Henrique Della TorreLetícia Esposito SewaybrickerThiago Salum FontanaEloisa Helena Rubello Valler CeleriGil Guerra JúniorPaulo Dalgalarrondo. (2015) Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. Journal of Child and Adolescent Psychopharmacology 25:10, pages 738-748.
Crossref
Crossref
Jian-Ping Zhang, Delbert G. Robinson, Juan A. Gallego, Majnu John, Jin Yu, Jean Addington, Mauricio Tohen, John M. Kane, Anil K. Malhotra & Todd Lencz. (2015)
Association of a Schizophrenia Risk Variant at the
DRD2
Locus With Antipsychotic Treatment Response in First-Episode Psychosis
. Schizophrenia Bulletin 41:6, pages 1248-1255.
Crossref
Crossref
Ravi Philip Rajkumar. (2015) A patient-centered model of the action of psychotropic drugs. Personalized Medicine Universe 4, pages 46-53.
Crossref
Crossref
Hooman Mirzakhani, Martijn S van Noorden, Jesse Swen, Ala Nozari & Henk-Jan Guchelaar. (2015) Pharmacogenetics in electroconvulsive therapy and adjunctive medications. Pharmacogenomics 16:9, pages 1015-1031.
Crossref
Crossref
Su Ling Young, Mark Taylor & Stephen M Lawrie. (2014)
“First do no harm.”
A systematic review of the prevalence and management of antipsychotic adverse effects
. Journal of Psychopharmacology 29:4, pages 353-362.
Crossref
Crossref
Christine L. Miller. (2015) The chemical interaction between adrenochrome, three different classes of antipsychotic drugs and metabolites of the kynurenine pathway. European Neuropsychopharmacology 25:3, pages 435-440.
Crossref
Crossref
J Frank, M Lang, S H Witt, J Strohmaier, D Rujescu, S Cichon, F Degenhardt, M M Nöthen, D A Collier, S Ripke, D Naber & M Rietschel. (2014) Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Molecular Psychiatry 20:2, pages 150-151.
Crossref
Crossref
V. A. Akhmedov. (2015) The development of functional gastrointestinal diseases: Genetic aspects. Terapevticheskii arkhiv 87:8, pages 119.
Crossref
Crossref
K. A. Kirnichnaya, D. N. Sosin, M. V. Ivanov, V. A. Mikhaylov, D. V. Ivashchenko, E. E. Ershov, A. E. Taraskina, R. F. Nasyrova & E. M. Krupitsky. (2015) Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115:4, pages 113.
Crossref
Crossref
Jiamei Lian, Xu-Feng Huang, Nagesh Pai & Chao Deng. (2015) Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A/2C bindings in rat brains. Progress in Neuro-Psychopharmacology and Biological Psychiatry 56, pages 75-80.
Crossref
Crossref
S. Mas, P Gassó, M.A. Ritter, C. Malagelada, M. Bernardo & A. Lafuente. (2015) Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway. European Neuropsychopharmacology 25:1, pages 51-59.
Crossref
Crossref
Naji C Salloum, Michael J McCarthy, Susan G Leckband & John R Kelsoe. (2014) Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Medicine 12:1.
Crossref
Crossref
Nuwan C. Hettige, Clement Zai, Monica Hazra, Carol Borlido, James L. Kennedy, John Strauss, Bernard Le Foll, Albert Wong, Gary Remington & Vincenzo De Luca. (2014) Use of candidate gene markers to guide antipsychotic dosage adjustment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 54, pages 315-320.
Crossref
Crossref
Diane H. Fredrikson, Heidi N. Boyda, Lurdes Tse, Zachary Whitney, Mark A. Pattison, Fred J. Ott, Laura Hansen & Alasdair M. Barr. (2014) Improving Metabolic and Cardiovascular Health at an Early Psychosis Intervention Program in Vancouver, Canada. Frontiers in Psychiatry 5.
Crossref
Crossref
Hao Tang, Olga O McGowan & Gavin P Reynolds. (2014) Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action. Pharmacogenomics 15:12, pages 1599-1609.
Crossref
Crossref
Matea Nikolac Perkovic, Gordana Nedic Erjavec, Maja Zivkovic, Marina Sagud, Suzana Uzun, Alma Mihaljevic-Peles, Oliver Kozumplik, Dorotea Muck-Seler & Nela Pivac. (2014) Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology 231:18, pages 3757-3764.
Crossref
Crossref
Lynn E. DeLisi. (2014) Ethical issues in the use of genetic testing of patients with schizophrenia and their families. Current Opinion in Psychiatry 27:3, pages 191-196.
Crossref
Crossref
Yi Zhang, Meijuan Chen, Jun Chen, Zhiguo Wu, Shunying Yu, Yiru Fang & Chen Zhang. (2014) Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology 231:10, pages 2211-2218.
Crossref
Crossref
Gavin P. Reynolds, Olga O. McGowan & Caroline F. Dalton. (2014) Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. British Journal of Clinical Pharmacology 77:4, pages 654-672.
Crossref
Crossref
Eva J Brandl, James L Kennedy & Daniel J Müller. (2014) Pharmacogenetics of Antipsychotics. The Canadian Journal of Psychiatry 59:2, pages 76-88.
Crossref
Crossref
Katarzyna Drozda, Daniel J. Müller & Jeffrey R. Bishop. (2014) Pharmacogenomic Testing for Neuropsychiatric Drugs: Current Status of Drug Labeling, Guidelines for Using Genetic Information, and Test Options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:2, pages 166-184.
Crossref
Crossref
Evangelia Eirini Tsermpini, Konstantinos Assimakopoulos, Marina Bartsakoulia, Gregoris Iconomou, Eleni Merkouri Papadima, Konstantinos Mitropoulos, Alessio Squassina & George P Patrinos. (2014) Individualizing clozapine and risperidone treatment for schizophrenia patients. Pharmacogenomics 15:1, pages 95-110.
Crossref
Crossref
Paul C Guest, Man K Chan, Michael G Gottschalk & Sabine Bahn. (2014) The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients. Biomarkers in Medicine 8:1, pages 15-27.
Crossref
Crossref
James J Crowley, Yunjung Kim, Alan B Lenarcic, Corey R Quackenbush, Cordelia J Barrick, Daniel E Adkins, Ginger S Shaw, Darla R Miller, Fernando Pardo-Manuel de Villena, Patrick F Sullivan & William Valdar. (2014) Genetics of Adverse Reactions to Haloperidol in a Mouse Diallel: A Drug–Placebo Experiment and Bayesian Causal Analysis. Genetics 196:1, pages 321-347.
Crossref
Crossref
Emilio Sacchetti, Antonio Vita, Alberto Siracusano & Wolfgang FleischhackerEmilio Sacchetti & Antonio Vita. 2014. Adherence to Antipsychotics in Schizophrenia. Adherence to Antipsychotics in Schizophrenia
1
84
.
Florence ThibautN. Ramoz, G. Voegeli & P. Gorwood. 2014. Apport des neurosciences à la psychiatrie clinique. Apport des neurosciences à la psychiatrie clinique
35
53
.
Jennie G. Pouget & Daniel J. Müller. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
557
587
.
Naomi R. Wray, Enda M. Byrne, Sven Stringer & Bryan J. Mowry. 2014. Behavior Genetics of Psychopathology. Behavior Genetics of Psychopathology
311
337
.
Britt I. Drögemöller, Galen E.B. Wright, Dana J.H. Niehaus, Robin Emsley & Louise Warnich. (2013) Next-generation sequencing of pharmacogenes. Pharmacogenetics and Genomics 23:12, pages 666-674.
Crossref
Crossref
Sashka Krumova, Blaga Rukova, Svetla Todinova, Lidia Gartcheva, Vihra Milanova, Draga Toncheva & Stefka G. Taneva. (2013) Calorimetric monitoring of the serum proteome in schizophrenia patients. Thermochimica Acta 572, pages 59-64.
Crossref
Crossref
Maja Zivković, Alma Mihaljević-Peles, Nada Bozina, Marina Sagud, Matea Nikolac-Perkovic, Bjanka Vuksan-Cusa & Dorotea Muck-Seler. (2013) The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol. Journal of Clinical Psychopharmacology 33:5, pages 593-599.
Crossref
Crossref
Harvey N. Kranzler & Sarah D. Cohen. (2013) Psychopharmacologic Treatment of Psychosis in Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America 22:4, pages 727-744.
Crossref
Crossref
Dana Ravyn, Vipa Ravyn, Robert Lowney & Henry A. Nasrallah. (2013) CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence. Schizophrenia Research 149:1-3, pages 1-14.
Crossref
Crossref
Chanchal Kumar & Alain J. van Gool. 2013. Comprehensive Biomarker Discovery and Validation for Clinical Application. Comprehensive Biomarker Discovery and Validation for Clinical Application
3
39
.
Wilma Knol, Rob J. van Marum, Paul A.F. Jansen, Eric Strengman, Asmar F.Y. Al Hadithy, Bob Wilffert, Alfred F.A.M. Schobben, Roel A. Ophoff & Toine C.G. Egberts. (2013) Genetic Variation and the Risk of Haloperidol-Related Parkinsonism in Elderly Patients. Journal of Clinical Psychopharmacology 33:3, pages 405-410.
Crossref
Crossref
Alberto ChiesaLoredana LiaChangsu HanSoo-Jung LeeChi-Un PaeAlessandro Serretti. (2013)
Investigation of Epistasis Between
DAOA
and
5HTR1A
Variants on Clinical Outcomes in Patients with Schizophrenia
. Genetic Testing and Molecular Biomarkers 17:6, pages 504-507.
Crossref
Crossref
Qingqing Xu, Xi Wu, Yuyu Xiong, Qinghe Xing, Lin He & Shengying Qin. (2013) Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Frontiers of Medicine 7:2, pages 180-190.
Crossref
Crossref
S. MUTSATSA & T. J. CURRID. (2013) Pharmacogenetics: a reality or misplaced optimism?. Journal of Psychiatric and Mental Health Nursing 20:4, pages 314-320.
Crossref
Crossref
Sergi Mas, Patricia Gassó, Miquel Bernardo & Amalia Lafuente. (2013) Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. European Neuropsychopharmacology 23:4, pages 329-337.
Crossref
Crossref
Fabian Czerwensky, Stefan Leucht & Werner Steimer. (2013) Association of the Common MC4R rs17782313 Polymorphism With Antipsychotic-Related Weight Gain. Journal of Clinical Psychopharmacology 33:1, pages 74-79.
Crossref
Crossref
Kyle J. Burghardt & Vicki L. Ellingrod. (2013) Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy. Molecular Diagnosis & Therapy 17:1, pages 21-30.
Crossref
Crossref
Cynthia S. Weickert, Thomas W. Weickert, Anil Pillai & Peter F. Buckley. (2013) Biomarkers in Schizophrenia: A Brief Conceptual Consideration. Disease Markers 35, pages 3-9.
Crossref
Crossref
Elizabeth A. Milward, Nilofar Daneshi & Daniel M. Johnstone. (2012) Emerging real-time technologies in molecular medicine and the evolution of integrated ‘pharmacomics’ approaches to personalized medicine and drug discovery. Pharmacology & Therapeutics 136:3, pages 295-304.
Crossref
Crossref
Sergi Mas, Adrián LLerena, Jerónimo Saíz, Miquel Bernardo & Amalia Lafuente. (2012) Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 13:15, pages 1773-1782.
Crossref
Crossref
Panagiotis Ferentinos & Dimitris Dikeos. (2012) Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Current Opinion in Psychiatry 25:5, pages 381-390.
Crossref
Crossref
Han-Ting Wei, Ya-Wen Lai, Mu-Hong Chen & Ying-Sheue Chen. (2012) Oral-paliperidone-induced tardive dyskinesia: a case report. General Hospital Psychiatry 34:5, pages 578.e5-578.e6.
Crossref
Crossref
Daniel J. MüllerEva J. BrandlRudi HwangArun K. TiwariJessica E. SturgessClement C. ZaiJeffrey A. LiebermanJames L. KennedyMargaret A. Richter. (2012)
The AmpliChip
®
CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism
. Genetic Testing and Molecular Biomarkers 16:8, pages 897-903.
Crossref
Crossref
A K Malhotra, J-P Zhang & T Lencz. (2011) Pharmacogenetics in psychiatry: translating research into clinical practice. Molecular Psychiatry 17:8, pages 760-769.
Crossref
Crossref
Henrik Berg Rasmussen & Christina Mackeprang Dahmcke. (2012) Genome-wide identification of structural variants in genes encoding drug targets. Pharmacogenetics and Genomics 22:7, pages 471-483.
Crossref
Crossref
Matcheri S KeshavanMatcheri S Keshavan. 2012. Pharmacological Treatments in Schizophrenia. Pharmacological Treatments in Schizophrenia
6
13
.
Michael Camilleri & David A. Katzka. (2012) Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology 302:10, pages G1075-G1084.
Crossref
Crossref
Raffael Massuda, Cristiano Chaves, Clarissa Trzesniak, Joao P. Machado-de-Sousa, Marcus V. Zanetti, Robin M. Murray, Wagner F. Gattaz & Geraldo F. Busatto. (2012) Meeting report: The Schizophrenia International Research Society (SIRS) South America Conference (August 5–7, 2011). Schizophrenia Research 137:1-3, pages 1-6.
Crossref
Crossref
Mohammed Shahid. 2012. Designing Multi-Target Drugs. Designing Multi-Target Drugs
14
31
.
Rudi Hwang, Arun K. Tiwari, Clement C. Zai, Daniel Felsky, Eli Remington, Tessa Wallace, Ryan P. Tong, Renan P. Souza, Gabriel Oh, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer & James L. Kennedy. (2012) Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration. Progress in Neuro-Psychopharmacology and Biological Psychiatry 37:1, pages 62-75.
Crossref
Crossref
Julia Staeker, Stefan Leucht & Werner Steimer. (2012) Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Pro12Ala. Molecular Diagnosis & Therapy 16:2, pages 93-98.
Crossref
Crossref
Michael Camilleri. (2012) The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology 9:3, pages 173-184.
Crossref
Crossref
Gavin P Reynolds. (2012) The Pharmacogenetics of Symptom Response to Antipsychotic Drugs. Psychiatry Investigation 9:1, pages 1.
Crossref
Crossref
Ramón Cacabelos, Rocío Martínez, Lucía Fernández-Novoa, Juan C. Carril, Valter Lombardi, Iván Carrera, Lola Corzo, Iván Tellado, Jerzy Leszek, Adam McKay & Masatoshi Takeda. (2012)
Genomics of Dementia:
APOE
- and
CYP2D6
-Related Pharmacogenetics
. International Journal of Alzheimer's Disease 2012, pages 1-37.
Crossref
Crossref
Gavin P. Reynolds. 2012. Current Antipsychotics. Current Antipsychotics
213
239
.